Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
March 30, 2023 16:05 ET
|
Eyenovia, Inc.
Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia...
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
March 23, 2023 08:00 ET
|
Eyenovia, Inc.
NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with...
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement
February 28, 2023 16:05 ET
|
Eyenovia, Inc.
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
February 15, 2023 09:51 ET
|
Eyenovia, Inc.
NEW YORK, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops
January 12, 2023 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
Eyenovia Announces Participation at the 2023 International Consumer Electronics Show
December 20, 2022 08:00 ET
|
Eyenovia, Inc.
Booth to feature “smart” remote patient monitoring capabilities being developed for future versions of the company’s novel Optejet® drug delivery technology Company to occupy booth 8311 NEW YORK,...
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
December 13, 2022 08:00 ET
|
Eyenovia, Inc.
Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the first product incorporating Eyenovia’s novel Optejet® drug delivery technology Company also announced receipt of...
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
December 08, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
November 29, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...
Eyenovia to Present at Upcoming BTIG Ophthalmology Day
November 23, 2022 16:05 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its...